Cancer patients who benefited can keep getting study drug

NCT ID NCT02632994

AVAILABLE Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This study is for cancer patients who took part in an earlier Eli Lilly study and were still benefiting from the treatment when that study ended. It allows them to keep receiving the study drug so their disease can continue to be managed. The main goal is to monitor long-term safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fort Wayne Oncology & Hematology
AVAILABLE

Fort Wayne, Indiana, 46804, United States

Contact Phone: •••-•••-••••

Contact
Sarah Cannon Cancer Center
AVAILABLE

Nashville, Tennessee, 37203, United States

Contact Phone: •••-•••-••••

Contact
UCLA Medical Center
AVAILABLE

Torrance, California, 90505, United States

Contact Phone: •••-•••-••••

Contact

Conditions

Explore the condition pages connected to this study.

CANCER